Evidence map›Paper›PMID 41589477›Full record

ArticleMolecular oncology2026

Tumor mutational burden as a determinant of metastatic dissemination patterns.

Eduardo Candeal, Andrea Moreno-Manuel, Miguel Salvadó-Pertierra, Cristina Santos-Vivas, Rebeca Sanz-Pamplona

Abstract read
In one paragraph

Article in Molecular oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Eduardo CandealCancer Heterogeneity and Immunomics (CHI), Clinical University Hospital Lozano Blesa, Aragon Health Research Institute (IISA), Zaragoza, Spain.ORCID 0009-0005-9961-433X
Andrea Moreno-ManuelCancer Heterogeneity and Immunomics (CHI), Clinical University Hospital Lozano Blesa, Aragon Health Research Institute (IISA), Zaragoza, Spain.ORCID 0000-0003-2996-2505
Miguel Salvadó-PertierraCancer Heterogeneity and Immunomics (CHI), Clinical University Hospital Lozano Blesa, Aragon Health Research Institute (IISA), Zaragoza, Spain.ORCID 0009-0003-3098-6675
Cristina Santos-VivasMedical Oncology Department, Catalan Institute of Oncology (ICO) - ONCOBELL, Barcelona, Spain.ORCID 0000-0002-9854-5097
Rebeca Sanz-PamplonaCancer Heterogeneity and Immunomics (CHI), Clinical University Hospital Lozano Blesa, Aragon Health Research Institute (IISA), Zaragoza, Spain.ORCID 0000-0002-2187-3527

Funding

Fundación Agencia Aragonesa para la Investigación y el DesarrolloInstituto de Salud Carlos III CB07/02/2005Instituto de Salud Carlos III PI20/00767Instituto de Salud Carlos III PI22/01938Ministerio de Ciencia, Innovación y Universidades CNS2022-136176
6 · The paper itself

Abstract

According to the seed and soil hypothesis, the organ specificity of metastasis is not a random process and depends on multiple tumor-intrinsic and microenvironmental factors. In this study, we characterized the mutational landscape of a large cohort of human metastatic samples to investigate whether mutational trends determine metastatic dissemination. Genomic data from nine cancer types (bladder, breast, colorectal, endometrial, melanoma, non-small cell lung cancer, ovarian, pancreatic, and prostate) including 19827 patients were obtained from a pan-cancer study. When restricting the analysis to driver mutations, no robust, recurrent mutational patterns associated with metastatic locations were identified across cancer types. However, when cancer types were analyzed separately, mutational trends associated with specific metastatic locations emerged. Considering the total tumor mutational burden (TMB), central nervous system (CNS)/brain and lung metastases harbored a higher TMB than other metastatic locations. Since higher TMB in CNS/brain metastases was also associated with improved prognosis, these findings may be pivotal in refining immunotherapy strategies. Indeed, this observation was confirmed in an independent dataset including patients treated with immunotherapy. In conclusion, our findings suggest that TMB may have greater influence on metastatic organotropism than driver mutational background.

Indexed as

MutationNeoplasm MetastasisNeoplasmsFemaleHumansPrognosisimmunotherapymetastasismutationsorganotropismprognostic biomarkerTMB

Identifiers

PMID41589477
PMCPMC13155152

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.